Skip to content

Ziverel for refractory reflux symptoms

Ziverel for PPI-refractory reflux symptoms: efficacy and mechanisms of action in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25733
Enrollment
22
Registered
2019-04-16
Start date
2019-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia

Interventions

Patients will receive the first period either a placebo or Ziverel four times daily for 14 days, followed by a second period in which they will receive the other study medication. There will be a wash

Sponsors

Amsterdam UMC, location AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Written informed consent - Both male and female patients will be included - Age above 18 years - Symptoms of heartburn and/or acid regurgitation under PPI treatment for at least 3 months. - A total reflux symptom score (measured through the Reflux Disease Questionnaire , RDQ) above 8 (24). - Use of proton pump inhibitors at a standard two times daily dose for at least 4 weeks prior to inclusion, same dosage should be maintained during the entire study period.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Previous gastric or major gastrointestinal surgery other than appendectomy or cholecystectomy. - Use of any other medication than proton pump inhibitors with a potential effect on gastrointestinal motility, secretion or sensitivity that cannot be stopped for the duration of the study (e.g. H2-blockers, antidepressants, prokinetics, antacids) - Known Barrett’s esophagus - History of gastrointestinal cancer - Known allergy to one of the ingredients of Ziverel - Severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) - Pregnant, lactating or fertile women (without contraception)

Design outcomes

Primary

MeasureTime frame
Acid perfusion sensitivity score (acid perfusion test).

Secondary

MeasureTime frame
- Symptom score improvement based on the RDQ Questionnaire score - Esophageal barrier function measured with Ussing chamber experiments and electrical tissue impedance spectroscopy during endoscopy.

Contacts

Public ContactRenske Oude Nijhuis

Amsterdam UMC

r.a.oudenijhuis@amsterdamumc.nl+31205667805

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)